BofA Securities initiated coverage on Embecta Corp. with a new price target
$EMBC
Medical/Dental Instruments
Health Care
BofA Securities initiated coverage of Embecta Corp. with a rating of Underperform and set a new price target of $25.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2025 | $15.00 | Neutral | Mizuho |
| 12/2/2024 | $13.00 → $20.00 | Underweight → Equal-Weight | Morgan Stanley |
| 11/27/2024 | $26.00 | Neutral → Buy | BTIG Research |
| 10/20/2023 | Peer Perform | Wolfe Research | |
| 1/6/2023 | $28.00 | Equal-Weight → Underweight | Morgan Stanley |
| 9/8/2022 | Neutral | BTIG Research | |
| 8/1/2022 | $33.00 | Equal-Weight | Morgan Stanley |
| 6/21/2022 | $25.00 | Underperform | BofA Securities |
Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00
Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously
BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
4 - Embecta Corp. (0001872789) (Issuer)
PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability
PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on
PARSIPPANY, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal second quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, May 9, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11:00 a.m. ET on May 9, 2025, via the embecta investor re
SD - Embecta Corp. (0001872789) (Filer)
8-K - Embecta Corp. (0001872789) (Filer)
SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)
PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: 2025 Goldman Sachs Tenth Annual Leveraged Finance and Credit Conference Management will host one-on-one investor meetings on Thursday, May 29, 2025, at Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA. 2025 Jefferies Global Healthcare Conference Management will host a fireside session on Thursday, June 5, 2025, at 4:55 p.m. EDT, at the Marriott Marquis, New York City. 2025 Goldma
PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation and present its long range financial plan ("LRP"). "Our Investor Day will provide a comprehensive view of our roadmap for transitioning embecta to growth. We look forward to sharing how we are positioning embecta for long-term success in an evolving healthcare landscape," said Dev Kurdikar, President and Chief Executive Officer. "Today, we reiterate our commitment to maintaining our leadership in insulin i
PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta" or the "Company") (NASDAQ:EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter's financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "In this challenging operating environment, we are raising key profitability
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G/A - Embecta Corp. (0001872789) (Subject)
SC 13G - Embecta Corp. (0001872789) (Subject)
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of
WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world. "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the